Skip to main content
Top
Published in: Clinical Reviews in Allergy & Immunology 1/2022

24-06-2021 | Abatacept

Precision Medicine in the Treatment of Primary Immune Deficiency Patients With Disorders of Immune Dysregulation

Authors: Mark Ballow, Jennifer W. Leiding

Published in: Clinical Reviews in Allergy & Immunology | Issue 1/2022

Login to get access

Abstract

There are now more than 450 described monogenic germline mutations for inborn errors of immunity that result in the loss of expression, loss of function (LOF), or gain in function (GOF) of the encoded protein. Molecular characterization of these inborn errors of immunity has not only allowed us to characterize on a genetic basis these immune deficiency disorders but has provided a better understanding of the immunobiology of these inborn errors of immunity. More recently, these advances have allowed us to apply targeted therapy or precision medicine in their treatment. Of particular interest related to this review are those inborn errors of immunity that result in gain-of-function (GOF) genetic abnormalities. Many of these inborn errors of immunity fall into a new category referred to as diseases of immune dysregulation in which many of the patients not only exhibit an increased susceptibility to infection but also have a clinical phenotype associated with autoimmune processes and lymphoproliferative disease.
Literature
1.
go back to reference Tangye SG, Al-Herz W, Bousfiha A et al (2020) Human inborn errors of immunity: 2019 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol 40:24–64CrossRef Tangye SG, Al-Herz W, Bousfiha A et al (2020) Human inborn errors of immunity: 2019 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol 40:24–64CrossRef
2.
go back to reference Leiding JW, Ballow M (2018) Precision medicine in the treatment of primary immunodeficiency diseases. Curr Opin Allergy Clin Immunol 18:159–166CrossRef Leiding JW, Ballow M (2018) Precision medicine in the treatment of primary immunodeficiency diseases. Curr Opin Allergy Clin Immunol 18:159–166CrossRef
3.
go back to reference Leiding JW, Forbes LR (2019) Mechanism-based precision therapy for the treatment of primary immunodeficiency and primary immunodysregulatory diseases. J Allergy Clin Immunol Pract 7:761–773CrossRef Leiding JW, Forbes LR (2019) Mechanism-based precision therapy for the treatment of primary immunodeficiency and primary immunodysregulatory diseases. J Allergy Clin Immunol Pract 7:761–773CrossRef
4.
go back to reference Tangye SG, Al-Herz W, Bousfiha A et al (2021) The ever-increasing array of novel inborn errors of immunity: an interim update by the IUIS Committee. J Clin Immunol 41:666–679CrossRef Tangye SG, Al-Herz W, Bousfiha A et al (2021) The ever-increasing array of novel inborn errors of immunity: an interim update by the IUIS Committee. J Clin Immunol 41:666–679CrossRef
5.
go back to reference Notarangelo LD, Bacchetta R, Casanova JL, Su HC (2020) Human inborn errors of immunity: an expanding universe. Sci Immunol 5 Notarangelo LD, Bacchetta R, Casanova JL, Su HC (2020) Human inborn errors of immunity: an expanding universe. Sci Immunol 5
6.
go back to reference Lucas CL, Chandra A, Nejentsev S, Condliffe AM, Okkenhaug K (2016) PI3Kd and primary immunodeficiencies. Nat Rev Immunol 16:702–714CrossRef Lucas CL, Chandra A, Nejentsev S, Condliffe AM, Okkenhaug K (2016) PI3Kd and primary immunodeficiencies. Nat Rev Immunol 16:702–714CrossRef
7.
go back to reference Angulo I, Vadas O, Garcon F et al (2013) Phosphoinositide 3-kinase d gene mutation predisposes to respiratory infection and airway damage. Science 342:866–871CrossRef Angulo I, Vadas O, Garcon F et al (2013) Phosphoinositide 3-kinase d gene mutation predisposes to respiratory infection and airway damage. Science 342:866–871CrossRef
8.
go back to reference Coulter TI, Chandra A, Bacon CM et al (2017) Clinical spectrum and features of activated phosphoinositide 3-kinase d syndromw: a large patient cohort study. J Allergy Clin Immunol 139:597–606CrossRef Coulter TI, Chandra A, Bacon CM et al (2017) Clinical spectrum and features of activated phosphoinositide 3-kinase d syndromw: a large patient cohort study. J Allergy Clin Immunol 139:597–606CrossRef
9.
go back to reference Elkaim E, Neven B, Bruneau J et al (2016) Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase d syndrome 2: a cohort study. J Allergy Clin Immunol 138 Elkaim E, Neven B, Bruneau J et al (2016) Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase d syndrome 2: a cohort study. J Allergy Clin Immunol 138
10.
go back to reference Maccari ME, Abolhassani H, Aghamohammadi A et al (2018) Disease evolution and response to rapamycin in activated phosphoinositide 3-kinase δ syndrome: the European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry. Front Immunol 9:543CrossRef Maccari ME, Abolhassani H, Aghamohammadi A et al (2018) Disease evolution and response to rapamycin in activated phosphoinositide 3-kinase δ syndrome: the European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry. Front Immunol 9:543CrossRef
11.
go back to reference Rao VK, Webster S, Dalm V et al (2017) Effective “activated PI3Kδ syndrome”-targeted therapy with the PI3Kδ inhibitor leniolisib. Blood 130:2307–2316CrossRef Rao VK, Webster S, Dalm V et al (2017) Effective “activated PI3Kδ syndrome”-targeted therapy with the PI3Kδ inhibitor leniolisib. Blood 130:2307–2316CrossRef
12.
go back to reference Bour-Jordan H, Esensten JH, Martinez-Llordella M, Penaranda C, Stumpf M, Bluestone JA (2011) Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of CD28/B7 family. Immunol Rev 241:180–205CrossRef Bour-Jordan H, Esensten JH, Martinez-Llordella M, Penaranda C, Stumpf M, Bluestone JA (2011) Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of CD28/B7 family. Immunol Rev 241:180–205CrossRef
13.
go back to reference Walker LS (2013) Treg and CTLA-4: two intertwining pathways to immune tolerance. J Autoimmun 45:49–57CrossRef Walker LS (2013) Treg and CTLA-4: two intertwining pathways to immune tolerance. J Autoimmun 45:49–57CrossRef
14.
go back to reference Qureshi OS, Zheng Y, Nakamura K et al (2011) Transendocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 332:600–603CrossRef Qureshi OS, Zheng Y, Nakamura K et al (2011) Transendocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 332:600–603CrossRef
15.
go back to reference Lo B, Zhang K, Lu W et al (2015) Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science 349:436–440CrossRef Lo B, Zhang K, Lu W et al (2015) Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science 349:436–440CrossRef
16.
go back to reference Kuehn HS, Ouyang W, Lo B et al (2014) Immune dysregulation in human subjects with heterozygous germlines mutations in CTLA4. Science 345:1623–1627CrossRef Kuehn HS, Ouyang W, Lo B et al (2014) Immune dysregulation in human subjects with heterozygous germlines mutations in CTLA4. Science 345:1623–1627CrossRef
17.
go back to reference Schubert D, Bode C, Kenefeck R et al (2014) Autosomal-dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med 20:1410–1416CrossRef Schubert D, Bode C, Kenefeck R et al (2014) Autosomal-dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med 20:1410–1416CrossRef
18.
go back to reference Lo B, Fritz JM, Su HC, Uzel G, Jordan MB, Lenardo MJ (2016) CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency. Blood 128:1037–1042CrossRef Lo B, Fritz JM, Su HC, Uzel G, Jordan MB, Lenardo MJ (2016) CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency. Blood 128:1037–1042CrossRef
19.
go back to reference Bonelli M, Scheinecker C (2018) How does abatacept really work in rheumatoid arthritis? Curr Opin Rheumatol 30:295–300CrossRef Bonelli M, Scheinecker C (2018) How does abatacept really work in rheumatoid arthritis? Curr Opin Rheumatol 30:295–300CrossRef
20.
go back to reference Lee S, Moon JS, Lee C et al (2016) Abatacept alleviates severe autoimmune symptoms in a patient carrying a de novo variant in CTLA-4. J Allergy Clin Immunol 137:327–330CrossRef Lee S, Moon JS, Lee C et al (2016) Abatacept alleviates severe autoimmune symptoms in a patient carrying a de novo variant in CTLA-4. J Allergy Clin Immunol 137:327–330CrossRef
21.
go back to reference van Leeuwen EM, Cuadrado E, Gerrits AM, Witteveen E, de Bree GJ (2018) Treatment of intracerebral lesions with abatacept in a CTLA4-haploinsufficient patient. J Clin Immunol 38:464–467CrossRef van Leeuwen EM, Cuadrado E, Gerrits AM, Witteveen E, de Bree GJ (2018) Treatment of intracerebral lesions with abatacept in a CTLA4-haploinsufficient patient. J Clin Immunol 38:464–467CrossRef
22.
go back to reference Villarino A, Kanno Y, O’Shea J (2017) Mechanisms and consequences of JAK-STAT signaling in the immune system. Nat Immunol 18:374–384CrossRef Villarino A, Kanno Y, O’Shea J (2017) Mechanisms and consequences of JAK-STAT signaling in the immune system. Nat Immunol 18:374–384CrossRef
23.
go back to reference van de Veerdonk FL, Plantinga TS, Hoischen A et al (2011) STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med 365:54–61CrossRef van de Veerdonk FL, Plantinga TS, Hoischen A et al (2011) STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med 365:54–61CrossRef
24.
go back to reference Toubiana J, Okada S, Hiller J et al (2016) Heterozygous STAT1 gain-of-function mutations underlie an unexpectly broad clinical phenotype. Blood 127:3154–3164CrossRef Toubiana J, Okada S, Hiller J et al (2016) Heterozygous STAT1 gain-of-function mutations underlie an unexpectly broad clinical phenotype. Blood 127:3154–3164CrossRef
25.
go back to reference Hartono SP, Vargas-Hernández A, Ponsford MJ et al (2018) Novel STAT1 gain-of-function mutation presenting as combined immunodeficiency. J Clin Immunol 38:753–756CrossRef Hartono SP, Vargas-Hernández A, Ponsford MJ et al (2018) Novel STAT1 gain-of-function mutation presenting as combined immunodeficiency. J Clin Immunol 38:753–756CrossRef
26.
go back to reference Uzel G, Sampaio EP, Lawrence MG et al (2013) Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation-polyendocrinopathy-enteropathy-X-linked-like syndrome. J Allergy Clin Immunol 131:1611–1623CrossRef Uzel G, Sampaio EP, Lawrence MG et al (2013) Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation-polyendocrinopathy-enteropathy-X-linked-like syndrome. J Allergy Clin Immunol 131:1611–1623CrossRef
27.
go back to reference Leiding JW, Okada S, Hagin D et al (2018) Hematopoietic stem cell transplantation in patients with gain-of-function signal transducer and activator of transcription 1 mutations. J Allergy Clin Immunol 141:704–17.e5CrossRef Leiding JW, Okada S, Hagin D et al (2018) Hematopoietic stem cell transplantation in patients with gain-of-function signal transducer and activator of transcription 1 mutations. J Allergy Clin Immunol 141:704–17.e5CrossRef
28.
go back to reference Forbes LR, Vogel TP, Cooper MA et al (2018) Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations. J Allergy Clin Immunol 142:1665–1669CrossRef Forbes LR, Vogel TP, Cooper MA et al (2018) Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations. J Allergy Clin Immunol 142:1665–1669CrossRef
29.
go back to reference Higgins E, Shehri TA, McAleer MA et al (2015) Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation. J Allergy Clin Immunol 135(551–3):e1–e3 Higgins E, Shehri TA, McAleer MA et al (2015) Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation. J Allergy Clin Immunol 135(551–3):e1–e3
30.
go back to reference Meesilpavikkai K, Dik WA, Schrijver B et al (2018) Baricitinib treatment in a patient with a gain-of-function mutation in signal transducer and activator of transcription 1 (STAT1). J Allergy Clin Immunol 142:328–30.e2CrossRef Meesilpavikkai K, Dik WA, Schrijver B et al (2018) Baricitinib treatment in a patient with a gain-of-function mutation in signal transducer and activator of transcription 1 (STAT1). J Allergy Clin Immunol 142:328–30.e2CrossRef
31.
go back to reference Weinacht KG, Charbonnier L, Alroqi F et al (2017) Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation. J Allergy Clin Immunol 139:1629–1640CrossRef Weinacht KG, Charbonnier L, Alroqi F et al (2017) Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation. J Allergy Clin Immunol 139:1629–1640CrossRef
Metadata
Title
Precision Medicine in the Treatment of Primary Immune Deficiency Patients With Disorders of Immune Dysregulation
Authors
Mark Ballow
Jennifer W. Leiding
Publication date
24-06-2021
Publisher
Springer US
Published in
Clinical Reviews in Allergy & Immunology / Issue 1/2022
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-021-08871-4

Other articles of this Issue 1/2022

Clinical Reviews in Allergy & Immunology 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine